Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
102.02
+0.47 (0.46%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Jazz Pharmaceuticals Revenue
In the year 2024, Jazz Pharmaceuticals had annual revenue of $4.07B with 6.12% growth. Jazz Pharmaceuticals had revenue of $1.09B in the quarter ending December 31, 2024, with 7.53% growth.
Revenue (ttm)
$4.07B
Revenue Growth
+6.12%
P/S Ratio
1.56
Revenue / Employee
$1,453,196
Employees
2,800
Market Cap
6.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.07B | 234.75M | 6.12% |
| Dec 31, 2023 | 3.83B | 174.83M | 4.78% |
| Dec 31, 2022 | 3.66B | 565.14M | 18.26% |
| Dec 31, 2021 | 3.09B | 730.67M | 30.91% |
| Dec 31, 2020 | 2.36B | 201.81M | 9.34% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
JAZZ News
- 10 days ago - Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out - Seeking Alpha
- 10 days ago - Jazz Pharma to pay $145 million to settle narcolepsy drug antitrust case - Reuters
- 24 days ago - Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference - PRNewsWire
- 4 weeks ago - Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting - PRNewsWire
- 5 weeks ago - CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX - Business Wire
- 6 weeks ago - Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline - Benzinga
- 6 weeks ago - Jazz Pharmaceuticals to buy Chimerix for $935 million - Reuters
- 6 weeks ago - Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio - GlobeNewsWire